Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss?
- Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — net loss of -$13.35M in Q1 2026.
- How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss changed year-over-year?
- Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss increased by 68.6% year-over-year, from -$42.45M to -$13.35M.
- What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss has grown at a 187.8% compound annual growth rate (CAGR), from -$5.22M to $124.45M.
- What does development and licensing of biopharmaceutical assets — net loss mean?
- This metric represents the bottom-line financial performance of the development and licensing segment after accounting for all revenues, operating expenses, and non-operating items. A net loss indicates that the costs associated with drug development, licensing activities, and overhead exceed the income generated during the period. It is a critical measure of the segment's current profitability and sustainability.